Clinical Trial: Superselective Intra-arterial Cerebral Infusion of Temsirolimus in HGG
Study Status: Completed
Recruit Status: RECRUITING
Condition: High Grade Glioma
Study Type: INTERVENTIONAL
Official Title: A Phase 0, Single-center, Open-label, Dose-escalating Trial Using Super-selective Intra-arterial Infusion of a Single Dose of Temsirolimus for the Treatment of Recurrent High-grade Glioma
Brief Summary:
This is a single-center, open-label, dose-escalating Phase 0 trial that will enroll participants with a confirmed diagnosed recurrent high-grade glioma (grade 3 or 4 per WHO criteria) targeting the mTOR pathway.Eligible participants will be administered a single infusion of temsirolimus through super-selective intra-arterial infusion or intravenous infusion.Participants will receive the study drug administration on the same day as the planned surgical resection of the tumor.
Read more